ClinicalTrials.gg
RecruitingNCT05256290Updated Nov 18, 2026

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

A Phase 1/2 interventional study of silevertinib monotherapy in Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer and Metastatic Lung Non-Small Cell Carcinoma, sponsored by Black Diamond Therapeutics, Inc.. Recruiting at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Black Diamond Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 7 months later.
Updated Nov 18, 2026Now RecruitingFirst site in Canada+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
591st of 3,001
220 · median 56
Started
2022
with 168 others
Phase 1/2
487 of 3,374
118 open now
Primary completion
2028-03
later than 564 of 893 live
Registered
2,664th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 591st largest by planned enrollment of the 3,001 interventional ones that give a count, is one of 169 that started in 2022, is one of 487 in phase 1/2, reaches primary completion later than 564 of the 893 other live ones, and was the 2,664th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.

Phase 1 enrollment is now complete. Phase 2 is currently ongoing.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Squamous Lung Cancer
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Lung Cancer
  • NSCLC
  • Advanced Lung Carcinoma
  • Epidermal Growth Factor Receptor C797S
  • Epidermal Growth Factor Receptor G719X
  • EGF-R Positive Non-Small Cell Lung Cancer
  • EGFR-TKI Resistant Mutation

Keywords

  • EGFR alterations
  • EGFR L858R
  • EGFR Exon 19 del
  • EGFR inhibitor
  • intrinsic resistance NSCLC EGFR
  • acquired resistance NSCLC EGFR
  • intracranial disease
  • brain metastases
  • central nervous system metastases
  • CNS metastases
  • uncommon NSCLC EGFR mutations
  • C797S acquired resistance EGFR mutation
  • non-classical NSCLC EGFR mutations
  • classical NSCLC EGFR mutations
  • EGFR PACC NSCLC mutations
  • EGFR E709A/G/K/Q/V
  • EGFR E709_T710delinsD/T
  • EGFR G719A/C/D/R/S
  • EGFR G724S
  • EGFR L718Q/V
  • EGFR L747S/P, L747_A750delinsP, L747_P753delinsS
  • Second-site EGFR mutation
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Phase 2 Eligibility:

Key Inclusion Criteria Required for locally advanced or NSCLC:

  • by 1.1 criteria.
  • Adequate bone marrow or organ function.
  • of ≥ 3 months.
  • Sufficient performance status.
  • Confirmed NSCLC, without small cell lung cancer transformation with or without .
  • Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):

    • Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
    • Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
    • Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
  • Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):

    • Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
    • EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
    • For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.

Key Exclusion Criteria:

  • Known resistant mutations in tumor tissue or by liquid (eg, T790M, MET).
  • Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
  • Any history of interstitial lung disease related to EGFR TKI use.
  • Symptomatic or radiographic .
  • Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
  • Unresolved toxicity from prior therapy.
  • Significant cardiovascular disease.
  • Major surgery within 4 weeks of study entry or planned during study.
  • Ongoing or recent anticancer therapy or radiation therapy.
  • Evidence of (other than study-specific malignancies) requiring active therapy within the next 2 years.
  • Active or C infection and/or known (HIV) carrier.
  • Poorly controlled gastrointestinal disorders.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)

    * Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M). * Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor * Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)

    Drug: silevertinib monotherapy

  • Experimental
    Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

    Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)

    Drug: silevertinib monotherapy

  • Experimental
    Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)

    Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)

    Drug: silevertinib monotherapy

  • Experimental
    Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

    Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD.

    Drug: silevertinib monotherapy

  • Experimental
    Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose

    Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD.

    Drug: silevertinib monotherapy

Interventions

  • DrugSilevertinibStudies of SilevertinibSilevertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

    Also known as: BDTX-1535

06

What researchers measure

Primary outcomes

  1. Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)

    Dose-limiting toxicities (DLTs) in Cycle 1

    Time frame: The first treatment 21-day cycle (Cycle 1)

  2. Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)

    Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1

    Time frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

  3. Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose

    Treatment-emergent adverse events

    Time frame: Through study completion, approximately 1 year

Secondary outcomes

  1. Phase 1: To assess the preliminary antitumor activity of silevertinib (BDTX-1535) by objective response as assessed by RECIST version 1.1 (for patients with NSCLC) or Response Assessment in Neuro-oncology (RANO) (for patients with GBM)

    Time frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

  2. Phase 2: To assess progression free survival by RECIST version 1.1

    Time frame: Day 1 every 2 cycles starting at Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

  3. Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)

    Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1

    Time frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

07

Study locations

19 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2028, 72 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 72 months is above that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Nov 2025 → Mar 2028 and completion Dec 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Feb 25, 2022
StartActual
Mar 31, 2022
Primary completionEst.
Mar 2028was Nov 2025
CompletionEst.
Jun 2028was Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 18, 2026
Sites
3 sites added, 9 sites removed — first site in Canada. 16 sites changed recruiting status (16 now recruiting)
Show 16 sites
  • University of Alabama · Birmingham, United Statesno status→Recruiting
  • Banner MD Anderson Cancer Center · Gilbert, United Statesno status→Recruiting
  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United Statesno status→Recruiting
  • Cedars Sinai Medical Center · Los Angeles, United Statesno status→Recruiting
  • Sibley Memorial Hospital Johns Hopkins Medicine · Washington D.C., United Statesno status→Recruiting
  • Mayo Clinic- Jacksonville · Jacksonville, United Statesno status→Recruiting
  • Miami Cancer Institute - Baptist Health South Florida · Miami, United Statesno status→Recruiting
  • UHP- University of Hawaii Cancer Center · Honolulu, United Statesno status→Recruiting
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University · Chicago, United Statesno status→Recruiting
  • Dana-Farber Cancer Institute · Boston, United Statesno status→Recruiting
  • Mayo Clinic- Rochester · Rochester, United Statesno status→Recruiting
  • Montefiore Medical Center · The Bronx, United Statesno status→Recruiting
  • University of Pittsburgh Medical Center - Hillman Cancer Center · Pittsburgh, United Statesno status→Recruiting
  • Tennessee Oncology · Nashville, United Statesno status→Recruiting
  • Inova Schar Cancer Institute · Fairfax, United Statesno status→Recruiting
  • Fred Hutchinson Cancer Center/University of Washington · Seattle, United Statesno status→Recruiting
Show 3 added (2 Canada, 1 United States)
  • Next Oncology · Fairfax, United States
  • BC Cancer Vancouver · Vancouver, Canada
  • The Princess Margaret Cancer Centre · Toronto, Canada
Show 9 removed
  • City of Hope Huntington Beach · Huntington Beach, United States
  • University of Kansas Cancer Center · Fairway, United States
  • Johns Hopkins Bayview Medical Center · Baltimore, United States
  • Siteman Cancer Center · St Louis, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
  • Columbia University Irving Medical Center · New York, United States
  • UNC Hospitals - Lineberger Comprehensive Cancer Center · Chapel Hill, United States
  • The University of Texas MD Anderson Cancer Center · Houston, United States
  • Next Ocology · Fairfax, United States
Nov 18, 2026
Primary completion
Nov 3, 2025→Mar 2028
Nov 18, 2026
Study completion
Dec 2027→Jun 2028
Nov 18, 2026
Enrollment
200→220
Nov 18, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedCohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutationmutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
  • EditedFor Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.
Nov 18, 2026
Interventions
Changed silevertinib (BDTX-1535) monotherapy→silevertinib monotherapy. Arm changed Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations→Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed); Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation→Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed); Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations→Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed). Arms added: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose
Nov 18, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedPhase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)Time frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
  • AddedPhase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD doseTime frame: Through study completion, approximately 1 year
Nov 18, 2026
Secondary outcomes
1 edited, 5 removed
What changed in the outcomes
  • EditedPhase 1 and Phase 2 Cohort 4 Only: To characterize the plasma concentrationassess antitumor efficacy of silevertinib (BDTX-1535) following single and multiple dosingTime frame: Cycle 1 Days 1, 2, 15, and 16, Cycles 2 to 5 Day 1, and Day 1 of every other cycle thereafter to study completion, approximately 1 year (each cycle is 21 days) → Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
  • RemovedPhase 1 and Phase 2: Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, approximately 1 year
  • RemovedPhase 1: To assess the effect of tablet formulation on the plasma concentration of silevertinib (BDTX-1535)Time frame: Two timepoints during the first cycle: Cycle 0 (7 days prior to Cycle 1 Day 1) and Cycle 1 Day 1 only (each cycle is 21 days)
  • RemovedPhase 1: To assess the effect of food on the plasma concentration of silevertinib (BDTX-1535)Time frame: Two timepoints during the first cycle: Cycle 0 (7 days prior to Cycle 1 Day 1) and Cycle 1 Day 1 only (each cycle is 21 days)
  • RemovedPhase 2: To assess duration of tumor response by RECIST version 1.1Time frame: Day 1 every 2 cycles starting at Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
  • RemovedPhase 2: To determine the optimal dosage of silevertinib (BDTX-1535) (100 mg or 200 mg daily dose)Time frame: At least the first treatment 21-day cycle (Cycle 1) for select patients enrolled into the Phase 2
Nov 18, 2026
Contact
Study contact now listed: added b•••@careboxhealth.com · •••4397. See the current contact
Nov 18, 2026
Site contacts
Changed at 16 sites. See the sites
Show 16 sites
  • University of Alabama · Birmingham, United StatesContact added a•••@uabmc.edu · •••6454
  • Banner MD Anderson Cancer Center · Gilbert, United StatesContact added B•••@bannerhealth.com · •••5488
  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United StatesContact added •••4763Contact added •••1133
  • Cedars Sinai Medical Center · Los Angeles, United StatesContact added G•••@cshs.org · •••0745
  • Sibley Memorial Hospital Johns Hopkins Medicine · Washington D.C., United StatesContact added s•••@live.johnshopkins.edu · •••6500
  • Mayo Clinic- Jacksonville · Jacksonville, United StatesContact added •••0015
  • Miami Cancer Institute - Baptist Health South Florida · Miami, United StatesContact added X•••@baptisthealth.net · •••7856
  • UHP- University of Hawaii Cancer Center · Honolulu, United StatesContact added •••3010
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University · Chicago, United StatesContact added c•••@northwestern.edu
  • Dana-Farber Cancer Institute · Boston, United StatesContact added d•••@dfci.harvard.edu · •••5119
  • Mayo Clinic- Rochester · Rochester, United StatesContact added •••0015
  • Montefiore Medical Center · The Bronx, United StatesContact added b•••@montefiore.org · •••8404
  • University of Pittsburgh Medical Center - Hillman Cancer Center · Pittsburgh, United StatesContact added r•••@upmc.edu
  • Tennessee Oncology · Nashville, United StatesContact added m•••@scri.com · •••5090
  • Inova Schar Cancer Institute · Fairfax, United StatesContact added S•••@inova.org · •••0213
  • Fred Hutchinson Cancer Center/University of Washington · Seattle, United StatesContact added s•••@fredhutch.org · •••6346
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Active, not recruiting→Recruiting
    3 sites added, 9 sites removed — first site in Canada. 16 sites changed recruiting status (16 now recruiting)
    Show 16 sites
    • University of Alabama · Birmingham, United Statesno status→Recruiting
    • Banner MD Anderson Cancer Center · Gilbert, United Statesno status→Recruiting
    • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United Statesno status→Recruiting
    • Cedars Sinai Medical Center · Los Angeles, United Statesno status→Recruiting
    • Sibley Memorial Hospital Johns Hopkins Medicine · Washington D.C., United Statesno status→Recruiting
    • Mayo Clinic- Jacksonville · Jacksonville, United Statesno status→Recruiting
    • Miami Cancer Institute - Baptist Health South Florida · Miami, United Statesno status→Recruiting
    • UHP- University of Hawaii Cancer Center · Honolulu, United Statesno status→Recruiting
    • Robert H. Lurie Comprehensive Cancer Center at Northwestern University · Chicago, United Statesno status→Recruiting
    • Dana-Farber Cancer Institute · Boston, United Statesno status→Recruiting
    • Mayo Clinic- Rochester · Rochester, United Statesno status→Recruiting
    • Montefiore Medical Center · The Bronx, United Statesno status→Recruiting
    • University of Pittsburgh Medical Center - Hillman Cancer Center · Pittsburgh, United Statesno status→Recruiting
    • Tennessee Oncology · Nashville, United Statesno status→Recruiting
    • Inova Schar Cancer Institute · Fairfax, United Statesno status→Recruiting
    • Fred Hutchinson Cancer Center/University of Washington · Seattle, United Statesno status→Recruiting
    Show 3 added (2 Canada, 1 United States)
    • Next Oncology · Fairfax, United States
    • BC Cancer Vancouver · Vancouver, Canada
    • The Princess Margaret Cancer Centre · Toronto, Canada
    Show 9 removed
    • City of Hope Huntington Beach · Huntington Beach, United States
    • University of Kansas Cancer Center · Fairway, United States
    • Johns Hopkins Bayview Medical Center · Baltimore, United States
    • Siteman Cancer Center · St Louis, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    • Columbia University Irving Medical Center · New York, United States
    • UNC Hospitals - Lineberger Comprehensive Cancer Center · Chapel Hill, United States
    • The University of Texas MD Anderson Cancer Center · Houston, United States
    • Next Ocology · Fairfax, United States
    Primary completion Nov 3, 2025→Mar 2028
    Study completion Dec 2027→Jun 2028
    Enrollment 200→220
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedCohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutationmutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
    • EditedFor Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedPhase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)Time frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
    • AddedPhase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD doseTime frame: Through study completion, approximately 1 year
    Secondary outcomes 1 edited, 5 removed
    What changed in the outcomes
    • EditedPhase 1 and Phase 2 Cohort 4 Only: To characterize the plasma concentrationassess antitumor efficacy of silevertinib (BDTX-1535) following single and multiple dosingTime frame: Cycle 1 Days 1, 2, 15, and 16, Cycles 2 to 5 Day 1, and Day 1 of every other cycle thereafter to study completion, approximately 1 year (each cycle is 21 days) → Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
    • RemovedPhase 1 and Phase 2: Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, approximately 1 year
    • RemovedPhase 1: To assess the effect of tablet formulation on the plasma concentration of silevertinib (BDTX-1535)Time frame: Two timepoints during the first cycle: Cycle 0 (7 days prior to Cycle 1 Day 1) and Cycle 1 Day 1 only (each cycle is 21 days)
    • RemovedPhase 1: To assess the effect of food on the plasma concentration of silevertinib (BDTX-1535)Time frame: Two timepoints during the first cycle: Cycle 0 (7 days prior to Cycle 1 Day 1) and Cycle 1 Day 1 only (each cycle is 21 days)
    • RemovedPhase 2: To assess duration of tumor response by RECIST version 1.1Time frame: Day 1 every 2 cycles starting at Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
    • RemovedPhase 2: To determine the optimal dosage of silevertinib (BDTX-1535) (100 mg or 200 mg daily dose)Time frame: At least the first treatment 21-day cycle (Cycle 1) for select patients enrolled into the Phase 2
    Interventions Changed silevertinib (BDTX-1535) monotherapy→silevertinib monotherapy. Arm changed Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations→Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed); Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation→Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed); Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations→Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed). Arms added: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose
    Contact Study contact now listed: added b•••@careboxhealth.com · •••4397. See the current contact
    Site contacts Changed at 16 sites. See the sites
    Show 16 sites
    • University of Alabama · Birmingham, United StatesContact added a•••@uabmc.edu · •••6454
    • Banner MD Anderson Cancer Center · Gilbert, United StatesContact added B•••@bannerhealth.com · •••5488
    • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United StatesContact added •••4763Contact added •••1133
    • Cedars Sinai Medical Center · Los Angeles, United StatesContact added G•••@cshs.org · •••0745
    • Sibley Memorial Hospital Johns Hopkins Medicine · Washington D.C., United StatesContact added s•••@live.johnshopkins.edu · •••6500
    • Mayo Clinic- Jacksonville · Jacksonville, United StatesContact added •••0015
    • Miami Cancer Institute - Baptist Health South Florida · Miami, United StatesContact added X•••@baptisthealth.net · •••7856
    • UHP- University of Hawaii Cancer Center · Honolulu, United StatesContact added •••3010
    • Robert H. Lurie Comprehensive Cancer Center at Northwestern University · Chicago, United StatesContact added c•••@northwestern.edu
    • Dana-Farber Cancer Institute · Boston, United StatesContact added d•••@dfci.harvard.edu · •••5119
    • Mayo Clinic- Rochester · Rochester, United StatesContact added •••0015
    • Montefiore Medical Center · The Bronx, United StatesContact added b•••@montefiore.org · •••8404
    • University of Pittsburgh Medical Center - Hillman Cancer Center · Pittsburgh, United StatesContact added r•••@upmc.edu
    • Tennessee Oncology · Nashville, United StatesContact added m•••@scri.com · •••5090
    • Inova Schar Cancer Institute · Fairfax, United StatesContact added S•••@inova.org · •••0213
    • Fred Hutchinson Cancer Center/University of Washington · Seattle, United StatesContact added s•••@fredhutch.org · •••6346

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05256290
Lead sponsor
Black Diamond Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Mar 31, 2022
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

BDTX Clinical Trial Navigation Service
Contact
blackdiamondtx@careboxhealth.com
(866) 955-4397
Black Diamond Therapeutics
study director · Black Diamond Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silevertinib

Start the discussion